Generics
20 February 2026 The new hire has “deep experience in high-stakes International Trade Commission proceedings”, whose specialisms include medical devices, pharma and genomics.
17 February 2026
9 February 2026
21 January 2026
15 January 2026
Latest Features
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
Generics
While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.
Biotechnology
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays a generic's launch but the patent is invalidated or there is a finding of non-infringement.
Generics
Generic drug makers are watching two cases that will determine whether pharmaceutical firms can deduct—rather than capitalise—legal fees for defending against patent infringement suits, say Carina Federico and Anne Li of Crowell & Moring.
Americas
Certain problems with the patent opposition process need to be addressed in order to protect patent owners, say Alejandro Luna and Luz Elena Elias of Olivares.
Africa
Government-led schemes to incentivise patents are leading to delays and prejudice against legitimate applicants. Tyron Grant of Spoor and Fisher explains how South Africa is tackling the problem.
More News
9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.
4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.
23 September 2025 As John Squires is confirmed as the US Patent and Trademark Office's new director, Sarah Speight gathers reaction, and asks: what would you ask the US’ chief IP executive?
18 September 2025 A UPC Court of Appeal decision establishes a new benchmark for what constitutes imminent infringement in pharmaceutical patent litigation, particularly regarding generics’ pre-launch preparations, writes Mike Gruber of Carpmaels & Ransford.
2 September 2025 A High Court decision clarifies how cross-undertakings work in patent disputes, rejecting claims for exceptional remedies beyond compensation.
20 August 2025 The Japanese pharma company has defended a key patent for a treatment that achieved record 2024 sales of over $6 billion—but a patent cliff looms.
23 July 2025 Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox